OSI will market Novantrone for cancer
Executive Summary
OSI will use a contract sales organization to market Novantrone for acute nonlymphocytic leukemia after licensing oncologic use of mitoxantrone from Serono. The product will allow OSI to build a sales force and experience in oncology field; the firm's lead R&D project is the oncologic Tarceva. OSI will be the fifth company to market Novantrone. The drug was developed by Lederle, licensed to Immunex, briefly owned by Amgen after it acquired Immunex, and licensed to Serono in November (1"The Pink Sheet" Nov. 18, 2002, p. 32). Serono will continue to market Novantrone for multiple sclerosis and book all U.S. sales for all indications...